


# THIS MONTH IN JNM

**Guiding cancer therapy:** Rajendran and Mankoff comment on the promise of noninvasive molecular imaging methods, including a tumor hypoxia approach featured in this month's *JNM*, for characterizing biologic processes within individual patients and thereby enhancing clinical decision making. . . . . **Page 855**

**Automating Parkinson's analysis:** Zubal and colleagues describe a fully automated striatal analysis program applied to dopamine transporter images in patients with early symptoms of suspected parkinsonism and compare its performance with that of a trained image-processing technologist. . . . . **Page 857**

**<sup>123</sup>I-SAP retention in amyloidosis:** Hazenberg and colleagues assess the diagnostic performance and prognostic value of a simple parameter describing extravascular <sup>123</sup>I-SAP retention in systemic amyloidosis. . . . . **Page 865**


**Imaging and thrombus age:** Brighton and colleagues report on the ability of <sup>99m</sup>Tc-recombinant tissue plasminogen activator imaging to differentiate recent thrombus formation from older thrombi in patients with deep vein thrombosis. . . . **Page 873**




**Optimal treatment in pediatric thyroid cancer:** Handkiewicz-Junak and colleagues detail the results of a retrospective study investigating combinations of treatments associated with decreased risk of locoregional recurrence in children with differentiated thyroid cancer. . . **Page 879**

**PET and scintigraphy in bone metastases:** Ito and colleagues compare the effectiveness of whole-body <sup>18</sup>F-FDG PET and <sup>99m</sup>Tc bone scintigraphy in detecting metastases in patients with differentiated

thyroid cancer after thyroidectomy and before <sup>131</sup>I therapy. . . . . **Page 889**





**Diffuse thyroid <sup>18</sup>F-FDG uptake:** Karantanis and colleagues explore the clinical significance of diffusely increased <sup>18</sup>F-FDG uptake in the thyroid gland as an incidental finding on PET/CT. . . **Page 896**




**Dual-tracer PET/CT in liver cancer:** Ho and colleagues describe the complementary roles of <sup>11</sup>C-acetate and <sup>18</sup>F-FDG tracers in the PET component of PET/CT detection of metastatic hepatocellular carcinoma. . . . . **Page 902**

**PET/CT registration in liver imaging:** Vogel and colleagues evaluate the effect of breathing motion differences on registration accuracy in PET and CT imaging of the liver and offer recommendations on scanner requirements, breath-hold protocols, and reporting. . . . . **Page 910**




**Granulocyte CSF, <sup>18</sup>F-FDG, and SUVs:** Doot and colleagues determine whether che-

motherapy and treatment with granulocyte colony-stimulating factor change blood clearance curves and, therefore, affect the relationship between <sup>18</sup>F-FDG metabolic rates and standard uptake values. . . **Page 920**




**Optimal metabolite curve fitting:** Wu and colleagues assess the adequacy of "fit" of 4 metabolite models for correction of arterial input function using data from individuals imaged with <sup>11</sup>C-WAY 100635 PET. . . . . **Page 926**

**Partial-volume effect in PET:** Soret and colleagues provide an educational overview of the partial-volume effect and its consequences in PET tumor imaging, along with correction models and suggested actions to reduce potential error. . . . . **Page 932**



**PET imaging of perinatal inflammation:** Kannan and colleagues explore small-animal <sup>11</sup>C-labeled tracer PET imaging of microglial activation as an indicator of inflammation and perinatal brain injury. . . . **Page 946**



**PET and myocardial glucose metabolism:**

Herrero and colleagues investigate whether compartmental modeling of 1-<sup>11</sup>C-glucose PET kinetics can be used for noninvasive measurement of myocardial glucose metabolism beyond its initial extraction. . . . **Page 955**

**Novel tumor-binding peptide:**

Zitzmann and colleagues describe the binding properties and pharmacokinetic behavior of a new radiolabeled peptide in both in vitro and in vivo models of follicular thyroid carcinoma. . . . **Page 965**

**PET in hypoxia-directed radiochemotherapy:**


Beck and colleagues report on the ability of small-animal PET using the hypoxia tracer <sup>18</sup>F-FAZA to predict the success of radiotherapy in combination with tirapazamine, a specific cytotoxin for hypoxic cells. . . . **Page 973**

**Nicotine and brown adipose tissue uptake:**

Baba and colleagues evaluate the effects of β-adrenergic agonists on <sup>18</sup>F-FDG uptake in brown adipose tissue in rats and offer cautions about the effects of nicotine on PET imaging. . . . . **Page 981**


**PET melanocortin receptor expression imaging:**

Cheng and colleagues investigate <sup>18</sup>F-FB-NAPamide as a promising molecular probe for α-melanocyte-stimulating hormone receptor-positive melanoma and describe initial studies in mice. . . . **Page 987**




**Antibody penetration in tumor tissue:**

Thurber and colleagues address the complexities of and kinetic barriers to tumor targeting in antibody-based therapeutics with a theoretical model that suggests that such therapies may be better suited to micrometastases than vascularized tumors. . . . . **Page 995**



**DNA nanoirradiation and cell kill:**

Reske and colleagues investigate whether selective nanoirradiation of DNA with Auger electrons emitted by <sup>123</sup>I-ITdU can induce apoptosis and break resistance to doxorubicin, β-, and γ-irradiation in leukemia cells. . . **Page 1000**




**3D radiobiologic dosimetry:**

Prideaux and colleagues use data from a <sup>131</sup>I-treated patient to create radiobiologic modeling that converts the spatial distribution of absorbed dose into biologically effective dose and equivalent uniform dose parameters. . . . . **Page 1008**

**Anti-<sup>18</sup>F-FACBC dosimetry:** Nye and colleagues evaluate the human whole-body radiation burden of anti-<sup>18</sup>F-FACBC, a recently developed ligand that permits PET evaluation of the L-amino acid transport system. . . . . **Page 1017**


**PET and coronary artery stenosis:**

Madar and colleagues report on the potential clinical utility of <sup>18</sup>F-FBnTP PET in assessing the severity of coronary artery stenosis in a canine model. . . **Page 1021**



**Imaging cardiac cell death:**

Zhu and colleagues characterize the temporal and spatial distribution of a <sup>99m</sup>Tc-labeled fusion protein of C2A and glutathione-S-transferase in a rat model of myocardial ischemia and reperfusion. . . . **Page 1031**



**ON THE COVER**

<sup>18</sup>F-FDG PET/CT has been found useful in evaluating hepatocellular carcinoma metastases, although its role in the diagnosis of primary hepatocellular carcinoma is more limited. Dual-tracer PET/CT with <sup>18</sup>F-FDG and <sup>11</sup>C-acetate has shown an incremental value and a complementary advantage over single-tracer imaging in the evaluation of hepatocellular carcinoma metastases. Some intrathoracic nodes showing increased <sup>18</sup>F-FDG activity could be noncalcified granulomatous nodes and, thus, false-positive for metastasis. This possibility can be minimized by correlating serial PET/CT with other ancillary findings.

SEE PAGE 908

